The TNFAIP2 (TNF alpha-induced protein 2, Uniprot: Q03169) was identified in our study as a predictor of better therapy response and was also upregulated in melanoma patients in correlation with long survival both in proteomic and in PD1 and CTLA4 immunotherapy transcriptomic cohorts. Here, TNFAIP2 is linked to melanoma.